All Oncology News

Treatment with an investigational allogeneic T-cell immunotherapy improved outcomes vs conventional transplant in patients with hematologic malignancies

Matching grant from Weill family creates collaborative research hub, uniting scientists from UCSF and Stanford Medicine to transform cancer care within a decade.

CER-1236 has received fast track designation from the FDA for the treatment of patients with acute myeloid leukemia.

Subcutaneous daratumumab monotherapy demonstrated a 24-month PFS rate of 79.9% in patients with high-risk smoldering multiple myeloma.

The VENTANA HER2 (4B5) test earned CE-IVDR approval in Europe to assess HER2 status in metastatic breast cancer and biliary tract cancer.

Misty D. Shields, MD, PhD, discusses the inefficacy of concurrent immunotherapy and chemoradiation in lung cancer and the debate surrounding PCI in SCLC.

Alison Schram, MD, discusses the potential clinical utility of PKMYT1-targeted agents in gynecologic malignancies.

The combination of ziftomenib and cytarabine/daunorubicin showed a manageable safety profile with early efficacy in NPM1-mutated and KMT2A-rearranged AML.

Favorable long-term outcomes were reported with brexu-cel in patients with B-ALL and low disease burden who achieved peak CAR T-cell expansion.

Zanubrutinib bested acalabrutinib plus venetoclax in terms of PFS in patients with treatment-naive, low-risk CLL.

Findings from a meta-analysis associated asciminib with improved efficacy and safety vs other TKIs in chronic myeloid leukemia.

First-line venetoclax plus azacitidine did not improve overall survival vs placebo plus azacitidine in treatment-naive, higher-risk MDS.

Continuous zanubrutinib improved PFS and showed a trend for improved OS vs fixed-duration venetoclax-based therapy in treatment-naive CLL/SLL.

A post hoc analysis demonstrated the efficacy of olutasidenib monotherapy in primary refractory patients with IDH1-mutant AML.

Olomorasib plus pembrolizumab has been granted breakthrough therapy designation by the FDA in first-line KRAS G12C–mutated NSCLC.

The FDA has granted breakthrough therapy designation to zongertinib in the first line for nonsquamous NSCLC harboring HER2 TKD activating mutations.

Findings suggest that treatment with an FGFR4 inhibitor can disrupt tumor spread in pancreatic cancer.

Christopher Phillips, PharmD, discusses the advantages of liquid drug formulations over tablets and capsules for select pediatric or adult patients with cancer.

Tisotumab vedotin is cleared in Hong Kong for the treatment of select patients with cervical cancer.

Michelle Monje, MD, PhD, highlights early efficacy data with a GD2-directed CAR T-cell therapy for H3K27M-mutant diffuse midline gliomas.

A shorter and less intense course of postoperative radiation plus chemotherapy was shown to be effective in HPV-positive oropharyngeal cancer.

The MMR IHC Panel pharmDx was certified in the EU as a companion diagnostic to identify patients with colorectal cancer eligible for nivolumab/ipilimumab.

Health Canada approved mirvetuximab soravtansine for folate receptor-alpha positive, platinum-resistant epithelial ovarian cancer.

The first part of a PMA seeking the approval of PredicineCARE as a companion diagnostic in bladder cancer was submitted to the FDA.

Jad Chahoud, MD, MPH, discusses preliminary efficacy data with zanzalintinib plus nivolumab with/without relatlimab in untreated, advanced clear cell RCC.

The chief oncology/hematology fellow at Weill Cornell Medicine details everything that he wishes he had known entering his first year of fellowship.

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in August 2025.

The development of ZW171 for gynecologic, thoracic, and GI cancers is being discontinued.

Raji Shameem, MD, discusses the significance of the FDA approval of NALIRIFOX and first-line treatment selection in metastatic pancreatic cancer.